News >

FDA Grants Priority Review to Frontline Brentuximab Vedotin for Hodgkin Lymphoma

Jason M. Broderick @jasoncology
Published: Tuesday, Jan 02, 2018

Clay Siegall, PhD
Clay Siegall, PhD
The FDA has granted a priority review to a supplemental biologics license application (sBLA) for brentuximab vedotin (Adcetris) in combination with Adriamycin, vinblastine, and dacarbazine (AVD) as a frontline treatment for advanced classical Hodgkin lymphoma, according to a statement from the company developing the CD30-targeted antibody-drug conjugate, Seattle Genetics.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Medical Crossfire®: Personalizing Care for Multiple Myeloma Patients: Current and Future Sequencing StrategiesMay 31, 20191.5
Publication Bottom Border
Border Publication